Vistagen Therapeutics, Inc. (VTGN) Form 8-K — Aug 14, 2026
Vistagen Therapeutics reported a fiscal 2027 first-quarter net loss of $13.0 million, improved from $15.1 million a year earlier, on revenue of $1.5 million driven mainly by $1.2 million recognized from the expiration of the exclusivity period under its Exclusive Negotiation Agreement with Fuji Pharma. The company ended the quarter with $31.7 million in cash, cash equivalents, and marketable securities and said those funds are sufficient to support operations into 2027 but are not expected to extend its runway more than a year from now — an explicit signal of a future financing need.
Key figures
- Revenue
- 1476000
- Total Assets
- 35736000
- Shares Outstanding
- 44381433
- Cash Runway
- sufficient into 2027 but not expected to extend more than a year from now
- Cash Burn Quarter
- approximately $13.7 million decline from $45.4M at March 31, 2026 to $31.7M at June 30, 2026
- Ga Expense Q1 FY27
- 3918000
- Rd Expense Q1 FY27
- 10906000
- Stockholders Equity
- 24481000
- Ga Expense Prior Year Q
- 4370000
- Rd Expense Prior Year Q
- 11678000
- Weighted Average Shares
- 42980174
- Fuji Pharma Revenue Recognition
- 1200000
- Fasedienol Subjects6 Month Exposure
- over 300
- Fasedienol Subjects Single Exposure
- over 1,500
- Fasedienol Subjects12 Month Exposure
- over 100
Price after filing
Close on the filing date to close N calendar days later (from $0.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.